Emma Walmsley, GSK CEO (MediaPunch Inc/Alamy)
September 15, 2023 04:13 PM EDTUpdated 04:34 PM
R&D

FDA ap­proves GSK's JAK in­hibitor for rare blood can­cer af­ter three-month de­lay

Lei Lei Wu

News Reporter

The FDA ap­proved a new JAK in­hibitor, mo­melo­tinib, from GSK for adults with the rare bone mar­row can­cer myelofi­bro­sis who al­so have ane­mia. The ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times